- Report
- November 2023
- 130 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- July 2023
- 224 Pages
Global
From €4766EUR$5,130USD£3,950GBP
- Report
- February 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- February 2024
- 200 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- May 2024
- 179 Pages
Global
From €5240EUR$5,450USD£4,496GBP
- Report
- April 2024
- 137 Pages
Global
From €3749EUR$3,899USD£3,216GBP
- Report
- March 2021
- 210 Pages
Global
From €2308EUR$2,400USD£1,980GBP
- Report
- January 2023
- 130 Pages
Global
From €2163EUR$2,250USD£1,856GBP
- Report
- April 2022
- 178 Pages
Global
From €3063EUR$3,185USD£2,627GBP
€4375EUR$4,550USD£3,753GBP
- Report
- March 2023
- 147 Pages
Global
From €5768EUR$5,999USD£4,948GBP
Selonsertib is a drug used to treat liver and kidney disorders. It is a selective inhibitor of the apoptosis signal-regulating kinase 1 (ASK1) enzyme, which is involved in the regulation of cell death and inflammation. Selonsertib is used to treat nonalcoholic steatohepatitis (NASH), a chronic liver disease, and primary biliary cholangitis (PBC), an autoimmune liver disease. It is also used to treat chronic kidney disease (CKD) caused by diabetes. Selonsertib is available in both oral and intravenous formulations.
Selonsertib is a relatively new drug, and is still in the early stages of development. It is being studied in clinical trials for its potential to treat a variety of liver and kidney disorders. The drug has shown promise in treating NASH and PBC, and is being studied for its potential to treat CKD.
Several companies are involved in the development and commercialization of Selonsertib. These include Gilead Sciences, Inc., Merck & Co., Inc., and AstraZeneca plc. Show Less Read more
